         PRESCRIPTION NOTIFICATION AMENDMENTS           GENERAL SESSION      STATE OF UTAH      Chief Sponsor   Brad L  Dee      Senate Sponsor                            LONG TITLE      General Description            This bill amends provisions related to biosimilar products in the Pharmacy Practice Act        Highlighted Provisions             This bill                   deletes the definition of biosimilar                   defines interchangeable biological product                   requires a pharmacist to notify the prescriber when a biological product is dispensed       if an interchangeable biological product is available                   establishes the methods of notifying a prescriber  and                  amends repealer language        Money Appropriated in this Bill             None       Other Special Clauses             None       Utah Code Sections Affected        AMENDS                  b        as enacted by Laws of Utah       Chapter                  I        as last amended by Laws of Utah       Chapter                   Be it enacted by the Legislature of the state of Utah             Section     Section      b       is amended to read                  b        Interchangeable biological products                  For the purposes of this section              a    Biological product   is as  means the same as that term is defined in    U S C        Sec                       b    biosimilar  is as defined in    U S C  Sec       and               c    interchangeable  is as defined in    U S C  Sec                    b    Interchangeable biological product  means a biological product that the federal       Food and Drug Administration              i   has              A   licensed  and             B   determined meets the standards for interchangeability pursuant to    U S C  Sec            k      or             ii   has determined is therapeutically equivalent as set forth in the latest edition of or       supplement to the federal Food and Drug Administration s Approved Drug Products with       Therapeutic Equivalence Evaluations                  A pharmacist or pharmacy intern dispensing a prescription order for a specific       biological product by brand or proprietary name may substitute  a biosimilar  an       interchangeable biological product for the prescribed biological product only if              a   the purchaser specifically requests or consents to the substitute of an       interchangeable  biosimilar  biological product               b   the biosimilar product has been determined by the United States Food and Drug       Administration to be interchangeable with the prescribed biological product                c    b   the interchangeable  biosimilar  biological product is permitted to move in       interstate commerce               d    c   the pharmacist or pharmacy intern counsels the patient on the use and the       expected response to the prescribed biological product  whether a substitute or not  and the       substitution is not otherwise prohibited by this chapter               e    d   the prescribing practitioner has not prohibited the substitution of an       interchangeable  biosimilar  biological product for the prescribed biological product  as       provided in Subsection      and              f    e   the substitution is not otherwise prohibited by law                   a    Each out of state mail service pharmacy dispensing an interchangeable        biosimilar  biological product as a substitute for another biological product into this state       shall              a   notify the patient of the substitution either by telephone or in writing     and             b    Each out of state mail service pharmacy shall  comply with the requirements of       this chapter with respect to an interchangeable  biosimilar  biological product substituted for       another biological product  including labeling and record keeping                  Pharmacists or pharmacy interns may not substitute without the prescriber s       authorization biological product prescriptions unless the product has been determined by the       United States Food and Drug Administration to be interchangeable with the prescribed       biological product                  A pharmacist or pharmacy intern who dispenses a prescription with an       interchangeable  biosimilar  biological product under this section assumes no greater liability       than would be incurred had the pharmacist or pharmacy intern dispensed the prescription with       the biological product prescribed                  a   If  in the opinion of the prescribing practitioner  it is in the best interest of the       patient that an interchangeable  biosimilar  biological product not be substituted for a       prescribed biological product  the practitioner may prohibit a substitution either by writing        dispense as written  or by signing in the appropriate space where two lines have been       preprinted on a prescription order and captioned  dispense as written  or  substitution       permitted               b   i   If the prescription is communicated orally by the prescribing practitioner to the       pharmacist or pharmacy intern  the practitioner shall direct the prohibition or substitution              ii   The pharmacist or pharmacy intern shall make a written note of the practioner s       direction by writing the name of the practitioner and the words  orally by  and the initials of       the pharmacist or pharmacy intern written after it                  A pharmacist or pharmacy intern who substitutes an interchangeable  biosimilar        biological product for a prescribed biological product shall communicate the substitution to the       purchaser   The interchangeable  biosimilar  biological product container shall be labeled with       the name of the interchangeable  biosimilar  biological product dispensed  and the pharmacist        pharmacy intern  or pharmacy technician shall indicate on the file copy of the prescription both       the name of the prescribed biological product and the name of the interchangeable  biosimilar        biological product dispensed in its place                   a   A pharmacist or pharmacy intern who substitutes an interchangeable biosimilar       product for a prescribed biological product shall                i   notify the prescriber in writing  by fax  telephone  or electronic transmission of the       substitution  as soon as practicable  but not later than three business days after dispensing the       interchangeable biosimilar product in place of the prescribed biological product  and               ii   include the name and manufacturer of the interchangeable biosimilar product       substituted                 b   This subsection is repealed on May                             Within a reasonable time following the dispensing of a biological product  the        dispensing pharmacist or the pharmacist s designee shall communicate to the prescriber the        specific product provided to the patient  including the name of the product and the        manufacturer   The communication shall be conveyed by making an entry in an interoperable        electronic medical records system or through an electronic prescribing technology or a        pharmacy record that is electronically accessible by the prescriber   Otherwise  the pharmacist        shall communicate the biological product dispensed to the prescriber using facsimile         telephone  electronic transmission  or other prevailing means  provided that communication        shall not be required where               a   there is no FDA approved interchangeable biological product for the product        prescribed  or              b   a refill prescription is not changed from the product dispensed on the prior filling of        the prescription                   The board shall maintain a link on its website to the current list of all        interchangeable biological products              Section     Section   I       is amended to read                I        Repeal dates    Title                       Subsection              b  is repealed July                             Subsection      b          is repealed on May           Legislative Review Note     as of                  AMOffice of Legislative Research and General Counsel  